STAINES, England--(BUSINESS WIRE)--Astellas Pharma Europe Ltd. (APEL) announced today that data presented at the European Association of Urology (EAU) congress in Paris, France, have shown that the investigational drug MDV3100 extended life by nearly 5 months, compared to placebo, in men with advanced prostate cancer, previously treated with chemotherapy.
